Clinical Observation of primary percutaneous coronary intervention combined with tirofiban therapy in treatment patients with acute ST-segment elevation myocardial infarction / 中国基层医药

ABSTRACT

Objective This study was conducted to investigate the clinical outcomes and safety of primary percutaneous coronary intervention(PCI) combined with tirofiban therapy in patients with acute ST segment elevation myocardial infarction(STEMI). Methods Seventy-one consecutive patients with acute STEMI were divided by random number table to primary PCI combined with tirofiban therapy group(Tirofiban group,25 cases) and primary PCI treatment alone group(Control group,46 cases). Left ventricular ejection fraction(LVEF) and major adverse cardiac events rates(MACE) during hospitalization period and at 30 days discharge and 180 days after discharge were compared between the two groups. Results TIMI grade flow was significantly different between the tirofiban group and control group after surgery. The LVEF and MACE were significantly different between two groups during hospitalization period and at 30 days after discharge. The MACE at 180 days followup was relatively reduced and LVEF was relatively improved in tirofiban group, but there was not significantly different. Conclusion Adjunctive therapy with tirofiban for patients with acute STEMI who underwent primary PCI was safe and effective.